Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
10,9 USD | -0,37% | +4,41% | -2,94% |
05/04 | Arbutus Biopharma verkrijgt gunstig vonnis in rechtszaak over Moderna-patenten | MT |
04/04 | Moderna krijgt tegenslag in rechtszaak tegen Arbutus | MT |
Omzet 2024 * | 625 mln. 583 mln. | Omzet 2025 * | 171 mln. 159 mln. | Marktkapitalisatie | 8,78 mld. 8,2 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,25 mld. 3,97 mld. | Nettowinst (verlies) 2025 * | -998 mln. -932 mln. | EV/omzet 2024 * | 3,97 x |
Nettoliquiditeiten 2024 * | 6,3 mld. 5,89 mld. | Nettoliquiditeiten 2025 * | 5,11 mld. 4,77 mld. | EV/omzet 2025 * | 21,5 x |
K/w-verhouding 2024 * |
2,09
x | K/w-verhouding 2025 * |
-8,56
x | Werknemers | 904 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 77,8% |
Recentste transcriptie over Roivant Sciences Ltd.
1 dag | -0,37% | ||
1 week | +4,41% | ||
Lopende maand | +3,42% | ||
1 maand | +7,39% | ||
3 maanden | +4,81% | ||
6 maanden | +25,00% | ||
Lopend jaar | -2,94% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 01-03-16 |
Richard Pulik
DFI | Director of Finance/CFO | - | 28-09-21 |
Eric Venker
PSD | President | 37 | 01-01-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 53 | 13-03-23 | |
Keith Manchester
BRD | Director/Board Member | 55 | 01-01-14 |
Dan Gold
BRD | Director/Board Member | 56 | 01-01-20 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.81% | 4 M€ | +20,15% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 10,9 | -0,37% | 2 837 387 |
23-04-24 | 10,94 | +3,21% | 4 978 898 |
22-04-24 | 10,6 | +1,34% | 5 323 946 |
19-04-24 | 10,46 | +0,97% | 4 664 389 |
18-04-24 | 10,36 | -0,77% | 3 419 753 |
uitgestelde koers Nasdaq, 24 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,94% | 8,78 mld. | |
+25,61% | 660 mld. | |
+25,87% | 562 mld. | |
-5,24% | 358 mld. | |
+16,49% | 322 mld. | |
+8,28% | 297 mld. | |
+7,09% | 219 mld. | |
-9,12% | 196 mld. | |
+5,01% | 199 mld. | |
-8,75% | 149 mld. |